ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Betamethasone

Also written as “Ropivacaine + Clonidine + Betamethasone”, “Fixed Dose Etoricoxib + Betamethasone” and “calcipotriol and betamethasone (LEO 80185 gel)”.

Its studies are mostly in Psoriasis · Bursitis · Hip Fractures · Rhinitis, led by 6 companies.

Drug pageBetamethasone: every studyMany companies study it; this page follows only the 8 they lead. All 123 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 17, 20068 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharmaits history only30 open or runningphase 3since Jan 17, 2006Jan 17, 2006none ahead
Abbottits history only10 open or runningphase 3since Dec 12, 2007Dec 12, 2007none ahead
Cartivaits history only10 open or runningphase 2since Feb 17, 2014Feb 17, 2014none ahead
Laboratorios Silanes S.A. de C.V.10 open or runningphase 3since Dec 28, 2025Dec 28, 2025none ahead
Merckits history only10 open or runningphase 4since Aug 20, 2009Aug 20, 2009none ahead
Tolmarits history only10 open or runningphase 1since Apr 6, 2017Apr 6, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Laboratorios Silanes S.A. de C.V. only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 28, 2025First study: phase 3 study in BursitisFirst studyNCT07328022 · 89 enrolled · Mexico

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Laboratorios Silanes S.A. de C.V. leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07328022Bursitis · Mexico3CompletedAug 20, 202589

How it is read

Names in the registry

  • “Ropivacaine + Clonidine + Betamethasone”, 3 entries
  • “Fixed Dose Etoricoxib + Betamethasone”, 1 entry
  • “calcipotriol and betamethasone (LEO 80185 gel)”, 1 entry
  • “Calcipotriol plus betamethasone”, 1 entry
  • “Calcipotriene/betamethasone gel and ointment”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.